drugset
drugset / Trial / NCT02951728

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

NCT02951728 ↗

Phase 1/2 Unknown 58 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma

Timeline

Start
2016-10
Primary completion
2019-05
Completion
2020-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 10 mg/m2 Intravenous
Subject Decitabine Small molecule 15 mg/m2 Intravenous
Subject Decitabine Small molecule 20 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma